Immunovant Drops 8% After IMVT-1402 Misses in Lupus

Roivant said Wednesday morning that IMVT-1402 (imeroprubart), the FcRn-blocking antibody it develops through Immunovant, failed a Phase 2b study in a form of lupus by not improving symptoms; Immunovant shares fell 8.18% to 34.24 and Roivant 2.33% to 37.33 as of 16:39 GMT.

Roivant Sciences (ROIV) told investors Wednesday morning that IMVT-1402, the anti-FcRn antibody also known as imeroprubart, failed a Phase 2b trial in a form of lupus. The drug did not improve patients' symptoms, according to the company. It is the first clear setback in a pipeline that both Roivant and its majority-owned subsidiary Immunovant (IMVT) have built their equity stories around.

The market took the news out of the subsidiary first. Immunovant traded at 34.24, down 8.18% from the previous close of 37.29, with an intraday range of 33.60 to 37.01 as of 16:39 GMT on Wednesday. Roivant, which owns the asset through its stake in Immunovant, slipped 2.33% to 37.33 against a prior close of 38.22, trading between 37.25 and 38.48. Both moves came on a soft tape: the S&P 500 tracker was off 0.65% at $768.39, the Nasdaq 100 proxy down 0.95% at $740.37 and the Dow tracker 0.60% lower at $514.91.

What an FcRn blocker is supposed to do

FcRn — the neonatal Fc receptor — is the cellular recycling system that keeps immunoglobulin G antibodies circulating in the blood instead of being degraded. Block it and total IgG levels fall. In diseases where the immune system attacks the body with its own antibodies, stripping out IgG has proven to be a credible way to quiet the disease. That mechanism is already validated in myasthenia gravis and a handful of other autoantibody-driven conditions, which is why a crowded field of drugmakers has chased it.

Lupus was always the harder ask. Systemic lupus and its variants involve immune complexes, complement activation and T-cell biology alongside pathogenic antibodies, and the field's history is littered with mechanisms that looked sound on paper and produced no separation from placebo in the clinic. Symptom-based endpoints in lupus studies are notoriously noisy, and placebo response rates are high. A Phase 2b that does not move symptoms is, on the face of it, a straightforward miss — the company's own framing, as reported by Endpoints News, is that the drug did not improve symptoms.

Why the subsidiary fell four times as hard as the parent

The split in Wednesday's share reaction is informative. Immunovant is effectively a single-platform company: IMVT-1402 and its predecessor molecule are the business. Roivant is a holding structure with multiple subsidiaries, so a disappointment in one asset dilutes across a wider base of value. That is the mechanical explanation for an 8.18% decline at the subsidiary against a 2.33% decline at the parent.

The read-through investors now have to price is not the lupus indication alone but what the miss says about the breadth of the FcRn thesis. Companies developing these drugs have argued that IgG reduction is a platform applicable across dozens of autoimmune conditions, and valuations have been built on the assumption that each new indication is an incremental shot on goal rather than an independent biology risk. A negative lupus result argues for the second view: that FcRn works where autoantibodies are the dominant driver and struggles where they are one input among several.

What remains in the IMVT-1402 program

Roivant has been running IMVT-1402 across a set of autoimmune indications, and the lupus study is one readout among several. The company did not, in Wednesday's disclosure as summarized, indicate changes to the rest of the development plan. For shareholders, the practical questions are narrow and answerable over the coming weeks:

Whether management discontinues lupus development outright or attempts a subset analysis to salvage a path forward in a defined patient population.
How much of the remaining spend was earmarked for lupus and whether that capital gets redeployed to indications with cleaner autoantibody biology.
Whether the trial produced the expected depth of IgG lowering. If it did, the failure is about disease biology; if it did not, it is a drug problem, and that would be considerably worse for the franchise.
Whether partners or competitors running FcRn agents in overlapping indications adjust their own programs in response.

Roivant has been running IMVT-1402 across a set of autoimmune indications, and the lupus study is one readout among several.

The distinction in that third point matters more than anything else in the release. An FcRn antibody that hits its pharmacodynamic target and still fails tells the field something about lupus. One that misses its pharmacodynamic target tells the market something about the molecule.

The valuation question now facing both tickers

Immunovant's equity has traded for years on the option value of indication expansion rather than on revenue. Removing one large indication from that option set — lupus is among the biggest autoimmune populations in commercial terms — takes a slice out of the sum-of-parts arithmetic that sell-side models rely on. The 8.18% move suggests the market had not assigned lupus an enormous probability of success, which is consistent with how investors have historically handicapped the indication. Had lupus been a consensus winner, the drawdown would have been far steeper.

For Roivant, the strategic calculus is different. The company's model is to hold a portfolio of subsidiaries and monetize the ones that work, and the FcRn franchise has been the flagship. A single failed Phase 2b does not undo that, but it does raise the bar for what the remaining IMVT-1402 readouts need to deliver before the parent can argue the franchise justifies its share of the group's value.

What to watch next: the full dataset, any management commentary on IgG reduction achieved in the trial, and the timing of the next indication readout. Until those land, both stocks are being priced on an incomplete picture of why the drug did not work.

Key facts

Immunovant (IMVT): 34.24, -8.18% (as of 16:39 GMT, Sep 23, 2026)
Roivant (ROIV): 37.33, -2.33% (as of 16:39 GMT, Sep 23, 2026)
Drug: IMVT-1402 / imeroprubart, an anti-FcRn antibody
Result: Phase 2b in a form of lupus; no improvement in symptoms

Frequently asked questions

What did Roivant announce about IMVT-1402?

Roivant said on Wednesday morning that IMVT-1402, also known as imeroprubart, failed a Phase 2b study in a form of lupus. The drug did not improve patients' symptoms in the trial. IMVT-1402 is an anti-FcRn antibody developed through Roivant's subsidiary Immunovant and is the centerpiece of the group's autoimmune pipeline.

How did the shares react?

Immunovant fell 8.18% to 34.24 as of 16:39 GMT on September 23, 2026, from a previous close of 37.29, with an intraday range of 33.60 to 37.01. Roivant declined 2.33% to 37.33 from a prior close of 38.22. Broad indices were also lower, with the S&P 500 tracker down 0.65% on the day.

What is an FcRn inhibitor and how does it work?

FcRn, the neonatal Fc receptor, recycles immunoglobulin G antibodies so they stay in circulation rather than being broken down. Blocking FcRn lowers total IgG levels. In diseases driven by antibodies that attack the patient's own tissue, reducing IgG can dampen disease activity. The mechanism has already been validated in conditions such as myasthenia gravis.

Why is lupus a difficult indication for this mechanism?

Lupus involves immune complexes, complement activation and T-cell biology in addition to pathogenic antibodies, so removing IgG alone may not be enough. Lupus trials also use symptom-based endpoints with high placebo response rates, which has made the indication a graveyard for mechanisms that looked promising in earlier-stage work or in related diseases.

Why did Immunovant fall much more than Roivant?

Immunovant is essentially a single-asset company built around the FcRn program, so a failed readout hits the whole business. Roivant is a holding company with several subsidiaries, which spreads the impact across a broader base of value. That structural difference explains an 8.18% decline at the subsidiary against 2.33% at the parent on the same news.

What should investors watch next?

The key detail is whether the trial achieved the expected depth of IgG lowering. If it did, the failure points to lupus biology rather than the molecule. Investors should also watch whether management discontinues lupus development, how remaining capital is redeployed across other IMVT-1402 indications, and the timing of the next readouts.

Sources

Roivant reports Phase 2b lupus failure for an FcRn drug — Endpoints News